

EXHIBIT 1

You are here : Home Page > About us

Welcome to sanofi-aventis in the United States



[About us](#) | [Products](#) | [Health Matters](#) | [Press](#) | [Investors](#) | [Careers](#) | [R&D](#) | [Social Responsibility](#)

[US Web Sites](#) [Contact us](#) [Sitemap](#)



- [Sanofi-aventis worldwide](#)
- [Sanofi-aventis in the US](#)
- [Facility Locations](#)
- [Packaging Services](#)
- [Corporate Compliance Program](#)
- [Our Values](#)

Contact us

sanofi-aventis
55 Corporate Drive
Bridgewater, NJ 08807

Tel: 800-981-2491

Via email

Sanofi-aventis in the U.S. Company Profile

Sanofi-aventis is one of the world's largest pharmaceutical companies. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, and vaccines.

Sanofi-aventis is listed in Paris (EUREONEXT: SAN) and in New York (NYSE: SNY).

In 2006, sanofi-aventis generated sales of approximately € 28.4 billion, invested more than € 4.4 billion in research and development, and employed approximately 100,000 people in its core business. Corporate headquarters are in Paris, France.

Sanofi-aventis conducts business in the U.S. through its headquarters in Bridgewater, New Jersey.

Sanofi-aventis worldwide

Sanofi-aventis is one of the world's largest pharmaceutical companies.

[► Read more](#)

Letter from our U.S. Chairman

Timothy Rothwell

Chairman, Group Pharmaceutical Activities

sanofi-aventis U.S.

[► Read more](#)



Corporate Information

Get more information about sanofi-aventis group

[► Read more](#)



November 07, 2007

Retrospective Analysis Finds that Initiation of Insulin Glargine in Patients with Type 2 Diabetes was Associated with a Lower Incidence Rate of Myocardial Infarction as Compared with NPH Insulin

[► Read more](#)

© 2005-2007 sanofi-aventis U.S., LLC. All rights reserved. Legal Notices and Disclaimers and Privacy Policy